- Home
- TTNP vs VRAX Comparison
TTNP vs VRAX Comparison
Compare TTNP & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- VRAX
- Stock Information
- Founded
- TTNP 1991
- VRAX 2013
- Country
- TTNP United States
- VRAX United Kingdom
- Employees
- TTNP N/A
- VRAX N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TTNP Health Care
- VRAX Health Care
- Exchange
- TTNP Nasdaq
- VRAX Nasdaq
- Market Cap
- TTNP 5.4M
- VRAX 4.4M
- IPO Year
- TTNP 1996
- VRAX 2022
- Fundamental
- Price
- TTNP $4.23
- VRAX $0.57
- Analyst Decision
- TTNP
- VRAX Strong Buy
- Analyst Count
- TTNP 0
- VRAX 1
- Target Price
- TTNP N/A
- VRAX $3.00
- AVG Volume (30 Days)
- TTNP 92.5K
- VRAX 1.4M
- Earning Date
- TTNP 08-14-2025
- VRAX 01-01-0001
- Dividend Yield
- TTNP N/A
- VRAX N/A
- EPS Growth
- TTNP N/A
- VRAX N/A
- EPS
- TTNP N/A
- VRAX N/A
- Revenue
- TTNP N/A
- VRAX $6,331.00
- Revenue This Year
- TTNP N/A
- VRAX $217,274.83
- Revenue Next Year
- TTNP N/A
- VRAX N/A
- P/E Ratio
- TTNP N/A
- VRAX N/A
- Revenue Growth
- TTNP N/A
- VRAX N/A
- 52 Week Low
- TTNP $3.03
- VRAX $0.52
- 52 Week High
- TTNP $6.43
- VRAX $4.44
- Technical
- Relative Strength Index (RSI)
- TTNP 45.73
- VRAX 30.37
- Support Level
- TTNP $3.58
- VRAX $0.56
- Resistance Level
- TTNP $4.45
- VRAX $0.65
- Average True Range (ATR)
- TTNP 0.37
- VRAX 0.05
- MACD
- TTNP -0.08
- VRAX -0.01
- Stochastic Oscillator
- TTNP 36.93
- VRAX 15.95
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).